Mendaera Reports 98% Success for Focalist System
San Mateo, California, August 12, 2026 Mendaera Inc. announced results from a new peer-reviewed prospective multispecialty study showing that...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Mateo, California, August 12, 2026 Mendaera Inc. announced results from a new peer-reviewed prospective multispecialty study showing that...
Brisbane, California, August 12, 2026 Freenome, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
